Technical Analysis for NRIX - Nurix Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 1.09% | |
| NR7 | Range Contraction | 4.24% | |
| Narrow Range Bar | Range Contraction | 4.24% | |
| Inside Day | Range Contraction | 4.24% | |
| Wide Bands | Range Expansion | 4.24% | |
| Wide Bands | Range Expansion | 1.35% | |
| Calm After Storm | Range Contraction | 3.82% | |
| NR7 | Range Contraction | 3.82% | |
| Wide Bands | Range Expansion | 3.82% |
| Alert | Time |
|---|---|
| Rose Above 10 DMA | 1 day ago |
| Up 3% | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| 10 DMA Resistance | 1 day ago |
| Up 2% | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 07/11/2024
Nurix Therapeutics, Inc. Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Treatment Of Cancer Lymphoma Enzymes Tyrosine Kinase Immune Disorders Small Molecule Therapies Gilead Sciences Bruton's Tyrosine Kinase Oncogene
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.12 |
| 52 Week Low | 4.22 |
| Average Volume | 1,104,016 |
| 200-Day Moving Average | 10.03 |
| 50-Day Moving Average | 14.45 |
| 20-Day Moving Average | 14.95 |
| 10-Day Moving Average | 15.72 |
| Average True Range | 1.03 |
| RSI (14) | 56.90 |
| ADX | 22.63 |
| +DI | 26.96 |
| -DI | 16.18 |
| Chandelier Exit (Long, 3 ATRs) | 14.20 |
| Chandelier Exit (Short, 3 ATRs) | 15.12 |
| Upper Bollinger Bands | 17.07 |
| Lower Bollinger Band | 12.82 |
| Percent B (%b) | 0.69 |
| BandWidth | 28.40 |
| MACD Line | 0.47 |
| MACD Signal Line | 0.46 |
| MACD Histogram | 0.0115 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.77 | ||||
| Resistance 3 (R3) | 16.78 | 16.46 | 16.60 | ||
| Resistance 2 (R2) | 16.46 | 16.20 | 16.45 | 16.54 | |
| Resistance 1 (R1) | 16.10 | 16.04 | 16.28 | 16.09 | 16.49 |
| Pivot Point | 15.78 | 15.78 | 15.87 | 15.77 | 15.78 |
| Support 1 (S1) | 15.42 | 15.52 | 15.60 | 15.41 | 15.01 |
| Support 2 (S2) | 15.10 | 15.36 | 15.09 | 14.96 | |
| Support 3 (S3) | 14.74 | 15.10 | 14.90 | ||
| Support 4 (S4) | 14.73 |
